LabGenomics Signs Contract with Major Korean General Hospitals for Industry-First 'NGS Cancer Companion Diagnostic Test'

Labgenomics announced on the 17th that it has signed a supply contract for the 'NGS (Next-Generation Sequencing) Companion Diagnostic Test (ODxTT)' service, used for targeted anticancer drug treatment in non-small cell lung cancer patients, with Konyang University Hospital Cancer Diagnosis Center, marking a first in the diagnostic industry.

While many diagnostic companies and large hospitals are striving to commercialize the ODxTT service, Labgenomics is attracting attention by being the first to introduce the service to a major domestic hospital.

Konyang University Hospital, opened in 2000, is a leading general hospital in the central region, equipped with a state-of-the-art cancer center funded with a budget of 30 billion KRW. It has established a specialized cancer treatment system where multiple departments collaborate according to cancer types, including the breast and thyroid cancer team, gastric cancer team, gynecologic cancer team, lung cancer team, colorectal cancer team, liver cancer team, prostate cancer team, and radiation oncology center. In particular, Konyang University Hospital already uses the NGS-based cancer gene panel service provided by Labgenomics, demonstrating high trust in the expertise and accuracy of NGS-based cancer gene testing, according to the company.

Lung cancer often shows no early symptoms, and many cases are already advanced at initial diagnosis, with frequent recurrence and metastasis, resulting in a high mortality rate. It is the leading cause of cancer death worldwide, and August 1st is designated as World Lung Cancer Day. The companion diagnostic gene test service introduced by Labgenomics accurately detects more than 20 gene mutations of non-small cell lung cancer using a very small amount of DNA, enabling the prescription of appropriate targeted anticancer drugs.

A company representative stated, “Since its establishment, Labgenomics has invested heavily in NGS-based gene analysis to build a technological entry barrier,” and added, “Based on the vast clinical diagnostic cases secured through providing cancer panel test services, we will solidify our market share in the NGS clinical market.”

He continued, “We will actively leverage the company’s strengths to sign ODxTT service contracts with other specialized large cancer hospitals and secure market leadership.”